What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation?-Reference-Cited by-同舟云学术

What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation?

Published:2016-05-01 Issue:9 Volume:73 Page:e229-e237
ISSN:1079-2082
Container-title:American Journal of Health-System Pharmacy
language:en
Short-container-title:

Author:

Basaraba Jade E.¹,Barry Arden R.²

Affiliation:

1. Mazankowski Alberta Heart Institute, Alberta Health Services, Edmonton, Canada, and Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada

2. Lower Mainland Pharmacy Services, Chilliwack, Canada, and Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada

Publisher

Oxford University Press (OUP)

Subject

Health Policy,Pharmacology

Link

http://academic.oup.com/ajhp/article-pdf/73/9/e229/28335247/ajhp0e229.pdf

Reference32 articles.

1. Heart disease and stroke statistics—2015 update: a report from the American Heart Association;Mozaffarian;Circulation,2015

2. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines;O’Gara;J Am Coll Cardiol,2013

3. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines;Amsterdam;J Am Coll Cardiol,2014

4. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions;Levine;J Am Coll Cardiol,2011

5. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial;Morice;J Am Coll Cardiol,2007

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI;BMC Cardiovascular Disorders;2021-01-07